The worldwide antibody drug conjugate market size is estimated to reach around USD 10.1 billion by 2026, this market is foreseen to develop with 26.3% CAGR during the forecast time period.

Market Dynamics

Significant progressions in linker technology combined with broad R&D exercises is probably going to drive the market. Antibody drug conjugates are a creative class of medication made out of antibody linked, through a chemical linker, to a cytotoxic medication. ADC is intended to profit by the high explicitness of monoclonal antibodies to convey strong cytotoxic compound specifically to antigen-communicating tumor cells.

Conventional chemotherapy is planned to destroy quickly developing tumor cells. Be that as it may, it can likewise healthy proliferating cells, which produces unfortunate reactions. Interestingly, ADC is intended to upsurge the viability of treatment and decline the foundational poisonous quality.

Expanding rate of cancer growth combined with developing geriatric populace are probably going to drive the market for Antibody-Drug Conjugates (ADC). Besides, major mechanical progressions are likewise adding to drive the development. As indicated by the World Health Organization (WHO), the quantity of individuals matured 65 years or more, is anticipated to achieve 16% of the all-out populace by 2050 from 7% in 2000. Maturing has turned into a generous hazard factor for various sicknesses including disease and others. Subsequently, the developing geriatric populace is relied upon to drive development of the market over the coming years.

Market Insights

Based on technology, the market is bifurcated into cleavable and non-cleavable linkers. These two are the most transcendent advancements used to connect cytotoxic anticancer specialists' payloads. For example, two of the top of the line ADCs-Adcetris and Kadcyla, contains cleavable and non-cleavable linkers.

It has been evaluated that cleavable linkers will observer the quickest development over the coming years attributable to the variables, for example, wide utilization of these linkers and greatest number of products in the pipeline. Moreover, in 2017 two new Pfizer's products Besponsa and Mylotarg, were affirmed for use in created areas and both contain cleavable linkers.

Market Segmentation

Market By Application

• Blood Cancer
  • Leukemia
  • Lymphoma
• Breast Cancer
• Ovarian Cancer
• Lung Cancer
• Brain Tumor

Market By End-user

• Hospitals
• Clinics
• ASC
• Homecare
• Others

Market By Technology

• Cleavable Linker
• Non-cleavable Linker

Market By Geography

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • Rest of MEA

Regional Insights

In 2017, North America was the biggest revenue producing region, trailed by Europe. The main consideration ascribing for their proceeded with strength incorporates the nearness of critical market players, for example, Seattle Genetics, Roche, Pfizer, and AbbVie. North America is the most settled market as far as the use of ADCs combined with entrenched medicinal services foundation, and patient mindfulness.

North America is anticipated to observe the quickest development over the estimate time frame as a large portion of the ADCs at present in pipeline are being produced in U.S. Additionally, the U.S. Nourishment and Drug Administration (FDA) is one of the principal administrative bodies to endorse ADC in U.S. Subsequently, these components are probably going to help showcase development in the area over the estimate time frame.

Market Participants

Few of the main player present in the global Antibody drug conjugate market are AbbVie Inc.; Seattle Genetics, Inc. .; F. Hoffmann-La Roche Ltd.; Takeda Pharmaceutical Company Limited and Pfizer Inc.